Beam Therapeutics, Inc. (BEAM)
29.66
+0.20
(+0.68%)
USD |
NASDAQ |
Sep 04, 16:00
30.36
+0.70
(+2.36%)
After-Hours: 20:00
Beam Therapeutics Research and Development Expense (Quarterly) : 95.10M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.10M |
| March 31, 2026 | 104.52M |
| December 31, 2025 | 99.28M |
| September 30, 2025 | 109.77M |
| June 30, 2025 | 101.76M |
| March 31, 2025 | 98.82M |
| December 31, 2024 | 101.44M |
| September 30, 2024 | 94.26M |
| June 30, 2024 | 87.04M |
| March 31, 2024 | 84.82M |
| December 31, 2023 | 140.08M |
| September 30, 2023 | 100.05M |
| June 30, 2023 | 97.61M |
| March 31, 2023 | 99.65M |
| December 31, 2022 | 86.34M |
| September 30, 2022 | 85.29M |
| Date | Value |
|---|---|
| June 30, 2022 | 74.56M |
| March 31, 2022 | 65.41M |
| December 31, 2021 | 96.78M |
| September 30, 2021 | 54.62M |
| June 30, 2021 | 45.58M |
| March 31, 2021 | 190.11M |
| December 31, 2020 | 32.45M |
| September 30, 2020 | 29.82M |
| June 30, 2020 | 19.35M |
| March 31, 2020 | 21.55M |
| December 31, 2019 | 20.22M |
| September 30, 2019 | 12.54M |
| June 30, 2019 | 12.68M |
| March 31, 2019 | 9.179M |
| December 31, 2018 | 9.852M |
| September 30, 2018 | 9.854M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Twist Bioscience Corp. | 18.02M |
| Prime Medicine, Inc. | 33.40M |
| Intellia Therapeutics, Inc. | 80.50M |
| Sana Biotechnology, Inc. | 36.08M |
| Sarepta Therapeutics, Inc. | 91.26M |